Research Papers:

IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling

Hyung-Mun Yun, Kyung-Ran Park, Eun-Cheol Kim, Sang Bae Han, Do Young Yoon _ and Jin Tae Hong

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:9061-9072. https://doi.org/10.18632/oncotarget.3197

Metrics: PDF 2054 views  |   HTML 2233 views  |   ?  


Hyung-Mun Yun1,*, Kyung-Ran Park1,*, Eun-Cheol Kim1, Sang Bae Han2, Do Young Yoon3, Jin Tae Hong2

1Department of Maxillofacial Tissue Regeneration, School of Dentistry and Research Center for Tooth & Periodontal Regeneration (MRC), Kyung Hee University, Seoul 130-701, Republic of Korea

2College of Pharmacy and Medical Research Center, Chungbuk National University, Heungduk-gu, Cheongju, Chungbuk 361-763, Republic of Korea

3Department of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, Seoul 150-716, Republic of Korea

*These authors have contributed equally to this work

Correspondence to:

Jin Tae Hong, e-mail: [email protected]

Keywords: IL-32α, colon cancer, TNFR1, RIP1

Received: January 01, 2015     Accepted: January 25, 2015     Published: April 13, 2015


Inflammation is associated with cancer-prone microenvironment, leading to cancer. IL-32 is expressed in chronic inflammation-linked human cancers. To investigate IL-32α in inflammation-linked colorectal carcinogenesis, we generated a strain of mice, expressing IL-32 (IL-32α-Tg). In IL-32α-Tg mice, azoxymethane (AOM)-induced colon cancer incidence was decreased, whereas expression of TNFR1 and TNFR1-medicated apoptosis was increased. Also, IL-32α increased ROS production to induce prolonged JNK activation. In colon cancer patients, IL-32α and TNFR1 were increased. These findings indicate that IL-32α suppressed colon cancer development by promoting the death signaling of TNFR1.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3197